Acute Disseminated Encephalomyelitis (ADEM) Cell Models for Research

Acute disseminated encephalomyelitis (ADEM) is a rare inflammatory demyelinating disease of the central nervous system that predominantly affects children, with an estimated incidence of 0.2 to 0.8 per 100,000 individuals per year (WHO, 2023). The disease often follows a viral or bacterial infection or vaccination, and is characterized by multifocal white matter lesions. Mortality is low (approximately 1-2%), but long-term neurological sequelae occur in up to 30% of patients. There is no specific ICD-10 code for ADEM; it is classified under G04.0 (acute disseminated encephalitis). Risk factors include recent infections (e.g., measles, varicella, influenza), vaccinations, and genetic predisposition (e.g., HLA-DRB1*01). Five-year survival is generally favorable (>95%), but relapse may occur, leading to a diagnosis of multiphasic ADEM or multiple sclerosis. (NCI, 2023).

ADEM serves as a valuable model for studying acute neuroinflammation and demyelination, with relevance to multiple sclerosis (MS) and other autoimmune neurological disorders. Key research questions include:

• • What triggers the autoimmune response against myelin antigens?
• • How do genetic variants in immune-related genes (e.g., HLA, MOG) influence susceptibility?
• • Can we identify biomarkers for early diagnosis and prognosis?

Public datasets such as GEO (GSE) and ClinVar provide genomic and transcriptomic data from ADEM patients. The disease is ideal for mechanistic studies using gene-edited cell models, particularly to dissect the role of specific genes in neuroinflammation and remyelination.

Although ADEM is not a neoplastic disease, its pathogenesis involves immune-mediated pathways that can be modeled using gene editing. Key pathways include:

1. T cell activation and differentiation:

• • Antigen presentation by HLA molecules to CD4+ T cells.
• • Th1 and Th17 polarization, driven by cytokines such as IL-12, IL-23, and TGF-beta.
• • Production of pro-inflammatory cytokines (IFN-gamma, IL-17, TNF-alpha).

2. Blood-brain barrier (BBB) disruption:

• • Matrix metalloproteinases (MMPs) degrade tight junction proteins.
• • Chemokine-mediated leukocyte transmigration (e.g., CCL2, CXCL10).

3. Demyelination and axonal damage:

• • Autoantibodies against myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP).
• • Complement activation and macrophage-mediated phagocytosis of myelin.

4. Regulatory T cell (Treg) dysfunction:

• • Impaired suppression of autoreactive T cells.
• • Genetic variants in FOXP3 and IL2RA associated with autoimmunity.

ADEM is not characterized by somatic mutations, but germline variants and polymorphisms in immune-related genes have been associated with susceptibility. The table below summarizes key genetic associations from ClinVar and GWAS studies.

Note: Frequencies are approximate and based on small cohort studies; data from ClinVar and NCBI Gene.

Several signaling networks are dysregulated in ADEM, offering targets for gene editing:

• • JAK/STAT pathway:
• • Cytokine receptors (IL-6R, IFNAR) activate JAK kinases.
• • STAT1/STAT3 translocate to nucleus, inducing pro-inflammatory genes.
• • NF-kB pathway:
• • TLR and TNF receptor signaling activate NF-kB.
• • Drives expression of cytokines, chemokines, and adhesion molecules.
• • PI3K/AKT/mTOR pathway:
• • Regulates T cell survival and metabolism.
• • Hyperactivation promotes effector T cell expansion.
• • MAPK/ERK pathway:
• • Mediates T cell receptor signaling and cytokine production.
• • Modulates BBB permeability.

Key nodes for CRISPR knockout studies include STAT3, NFKB1, PIK3CD, and MAPK1.

Several cell lines and organoid models are used to study ADEM pathogenesis. These include immune cells, neural cells, and BBB models.

Organoids: Brain organoids derived from iPSCs can model neuroinflammation and demyelination in a 3D context, offering advantages for studying cell-cell interactions and drug responses.

Animal models are essential for understanding ADEM pathogenesis and testing therapies.

• • Experimental autoimmune encephalomyelitis (EAE):
• • Induced by immunization with myelin antigens (e.g., MOG, MBP) or adoptive transfer of autoreactive T cells.
• • Recapitulates many features of ADEM, including inflammation and demyelination.
• • Genetic models:
• • MOG-specific T cell receptor transgenic mice.
• • HLA-DRB1*01 transgenic mice.
• • Viral models:
• • Theiler's murine encephalomyelitis virus (TMEV) infection in mice.
• • Measles virus-induced encephalomyelitis in rodents.
• • Humanized models:
• • Mice engrafted with human immune cells or iPSC-derived microglia.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise genetic modifications, such as knockouts, knock-ins, and point mutations. These models are invaluable for dissecting ADEM pathogenesis and validating drug targets.

Examples of gene-edited cell models for ADEM research:

• • MOG knockout in SH-SY5Y or iPSC-derived oligodendrocytes: to study the role of MOG in demyelination and autoantibody targeting.
• • HLA-DRB1*01 knock-in in Jurkat or THP-1 cells: to model antigen presentation and T cell activation.
• • IL2RA knockout in primary T cells or Jurkat: to investigate Treg dysfunction.
• • Cytokine reporter lines (e.g., IL-17-GFP) in THP-1 or Jurkat: for high-throughput screening of anti-inflammatory compounds.

Commercially available, sequence-verified gene-edited cell models can accelerate research by providing reproducible and validated tools. These models are generated using CRISPR and other gene editing technologies, and are available from commercial sources without naming specific companies.

Gene-edited cell lines enable functional validation of candidate genes identified from GWAS or transcriptomic studies. For example:

• • Knockout of MOG in oligodendrocyte precursor cells can confirm its role in myelin formation and immune recognition.
• • Knock-in of HLA-DRB1*01 in antigen-presenting cells can elucidate how specific HLA alleles present myelin antigens.
• • CRISPR interference (CRISPRi) screens can identify genes that regulate cytokine production in T cells.

These studies provide mechanistic insights and prioritize targets for therapeutic intervention.

Isogenic pairs of gene-edited cells (e.g., wild-type vs. knockout) are powerful tools for drug screening. Applications include:

• • High-throughput screening of anti-inflammatory compounds using cytokine reporter lines.
• • Testing of drugs that modulate BBB permeability in hCMEC/D3 knockout models.
• • Modeling resistance to corticosteroids, the first-line treatment for ADEM, by generating glucocorticoid receptor (NR3C1) knockout lines.
• • Identifying synergistic drug combinations using CRISPR screens.

CRISPR synthetic lethality screens can uncover genetic dependencies and biomarkers. For ADEM:

• • Genome-wide knockout screens in immune cells treated with inflammatory stimuli can identify genes essential for survival or cytokine production.
• • These genes may serve as biomarkers for disease severity or treatment response.
• • Validation using patient samples from GEO or ClinVar can confirm clinical relevance.